



IPAMC/34(IV)/22-23

March 20, 2023

To,
National Stock Exchange of India Ltd
Exchange Plaza,
Bandra-Kurla Complex, Bandra(E),
Mumbai - 400 051.

Sub: Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations 2011

Dear Sir/Madam,

This is to inform you that ICICI Prudential Mutual Fund (the Fund) under its various schemes holds equity shares of Windlas Biotech Limited (the Company).

The Fund had made last disclosure under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as on April 21, 2022 wherein the Fund held 7.26% of the Company's then Paid up equity shares of 2,17,94,375.

The Company had announced Buyback of the shares on November 18, 2022, which began from November 21, 2022 and is ongoing.

In this regard, kindly note that one of the schemes of the Fund had carried out its last purchase transaction of 30,000 shares of your Company on December 15, 2022 which resulted in aggregate holding of the Fund at 8.98% of the Company's then paid up equity shares of 2,17,94,375. It may be noted that since then there has been no purchase transaction carried out by the Fund.

As on March 20, 2023, the paid up equity shares of the Company updated on NSE website is 2,12,39,831 and on BSE website is 2,13,42,526. Bloomberg (the investment monitoring system used by the Fund) updated the paid up equity shares to 2,11,09,064 on March 20, 2023 which was later confirmed by the Company vide mail dated March 20, 2023.

Post consideration of the revised paid up equity shares of 2,11,09,064, the holding of the Fund stands at 9.28%. As a result, the shareholding of the Fund has increased by more than 2% as compared to the previous disclosure on April 21, 2022 for 7.26% (for positions held as on April 19, 2022).

In the view of the above, we hereby file details of holdings as on March 19, 2023 pursuant to the aforesaid corporate action.

Name Of The Scheme	Number of Shares held	% Of Shares/Voting Rights To Total Paid Up Capital
ICICI Prudential Smallcap Fund	11,00,485	5.213
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund	8,57,651	4.063
Total	19,58,136	9.276



124



The holding by schemes of the Fund are from an investment perspective and not with the objective of seeking any controlling interest. Further, the updated disclosures pursuant to change in the paid up equity shares of the Company is enclosed herewith.

Please let us know if any disclosure is required under SEBI (Prohibition of Insider Trading) Regulations, 2015. If you require any further information, please feel free to contact us.

Thanking you.

For ICICI Prudential Asset Management Company Limited

R R Shetty

Rakesh Shetty

Head – Compliance & Company Secretary

Encl: As above





Format for Disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

PART – A – Details of the Acquisition

Name of the Target Company (TC)	Windlas Biotech Ltd.		
Name(s) of the acquirer/Seller and Person Acting in Concert (PAC) with the acquirer	ICICI Prudential Mutual Fund		
Whether the acquirer/Seller belongs to Promoter/Promoter group	No		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Limited, National Stock Exchange Limited		
Details of the acquisition/disposal as follows	Number	% w.r.t. total shares /voting capital wherever applicable(*)	% w.r.t. total diluted share / voting capital of the TC (**)
Before the acquisition under consideration, holding of acquirer along with PACs of:			
a) Shares carrying voting rights	15,83,045	7.263%	7.26%
b) Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/others)	--	--	--
c) Voting rights (VR) otherwise than by equity shares	--	--	--
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	--	--	--
e) Total (a+b+c+d)	15,83,045	7.263%	7.264%
Details of purchase			
a) Shares carrying voting rights acquired.	3,75,091	2.013%@	2.013%@
b) VRs acquired otherwise than by equity shares	--	--	--
c) Warrants/convertible securities/ any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired	--	--	--
d) Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/others)	--	--	--
e) Total (a+b+c+/-d)	19,58,136	9.276%	9.276%



ICICI Prudential Asset Management Company Limited
Corporate Identity Number: U99999DL1993PLC054135

Corporate Office: One BKC 13th Floor, Bandra Kurla Complex, Mumbai – 400051.

Tel: +91 22 2652 5000 Fax: +91 22 2652 8100, website: www.icicipruamc.com, email id: enquiry@icicipruamc.com

Central Service Office: 2nd Floor, Block B-2, Nirlon Knowledge Park, Western Express Highway, Mumbai - 400063.

Tel: 022 2685 2000 Fax: 022 26868313

After the acquisition, holding of acquirer along with PACs of:			
a) Shares carrying voting rights	19,58,136	9.276%	9.276%
b) Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/others) Shares pledged with the acquirer	--	--	--
c) VRs otherwise than by equity shares	--	--	--
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	--	--	-- s
e) Total (a+b+c+d)	19,58,136	9.276%	9.276%
(Note: the percentages have been rounded off to the nearest number)			
Mode of purchase (e.g. open market/public issue/rights issue/preferential allotment/inter transfer/encumbrance, etc.)	Secondary Market		
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc.	N.A.		
Date of purchase of/date of receipt of intimation of allotment of shares/VR/warrants/convertible securities/any other instrument that entitles the acquirer/seller to receive shares in the TC.	The aforesaid net acquisition was made during the period April 20, 2022 till March 19, 2023		
@Equity share capital/total voting capital of the TC before the said acquisition	₹ 10,55,45,320 comprising of 2,11,09,064 shares of face value 5/- each		
@Equity share capital/total voting capital of the TC after the said acquisition	₹ 10,55,45,320 comprising of 2,11,09,064 shares of face value 5/- each		
@Total diluted share/voting capital of the TC after the said acquisition	₹ 10,55,45,320 comprising of 2,11,09,064 shares of face value 5/- each		
Note. —			
(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.			
(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.			
@ Updated Paid up equity shares is 2,11,09,064 due to buyback of shares which is confirmed by the Company vide mail dated March 20, 2023.			
Signature of the acquirer/seller/Authorized Signatory			
Place : Mumbai		Date : March 20, 2023	
			